Steroid bill excludes AERs
This article was originally published in The Tan Sheet
Executive Summary
Senate Judiciary Committee approves the Anabolic Steroid Control Act (S 2195) Sept. 30 without language establishing mandatory adverse event reporting for supplements urged by Sen. Richard Durbin (D-Ill.). Durbin and committee Chair Orrin Hatch (R-Utah) agreed in June to work together to develop AER legislation with input from industry and other stakeholders. Hatch noted at the time the steroid bill could serve as a vehicle for AER language (1"The Tan Sheet" June 28, 2004, p. 3). According to staffers, the senators have worked out language which is likely to appear in a separate bill. Steroid control bill, which would ban androstenedione and a number of other steroid precursors, retains a controversial exemption for dehydroepiandrosterone (DHEA), along with estrogens and corticosteroids. The House passed a version of the bill in June (2"The Tan Sheet" June 7, 2004, p. 13)...
You may also be interested in...
Senators Durbin, Hatch To Work Together On AER Plan
Dietary supplement industry critic Sen. Richard Durbin (D-Ill.) will work alongside congressional industry supporters to develop legislation to create a mandatory serious adverse event reporting system
Anabolic Steroid Act Heads To Senate After Clearing House 408-3
The Anabolic Steroid Control Act was sent to the Senate June 3 after passing the House with its exemption for dehydroepiandrosterone intact
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.